The study, published in Lancet, reaffirms that being obese and overweight can be a major health burden and can lead to various other diseases.
Higher BMI increased individuals’ risks for 10 common cancers, according to results of a population-based cohort study conducted in the United Kingdom.
More than 12,000 cases of these malignancies each year in the UK can be attributed to patients being overweight or obese, and nearly 4,000 more of these cancers could occur each year if the average BMI of the country’s population continues to increase, results showed.
“The number of people who are overweight or obese is rapidly increasing, both in the UK and worldwide,” researcher Krishnan Bhaskaran, PhD, a National Institute for Health Research postdoctoral fellow at London School of Hygiene & Tropical Medicine, said in a press release. “It is well recognized that this is likely to cause more diabetes and cardiovascular disease. Our results show that if these trends continue, we can also expect to see substantially more cancers as a result.”
Bhaskaran and colleagues collected data from the UK Clinical Practice Research Datalink, which contains primary care records from about 9% of the country’s population. Researchers used the data — which include information about specialist referrals, hospital admissions and diagnoses made in secondary care — to assess the associations between BMI and 22 common cancers.
Read the report here: http://bit.ly/1yACubh
Source: Healio
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More